Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909)

Research output: Book/Report › Commissioned report

Original language	English
Publisher	National Institute for Health and Care Excellence
Publication status	Published - 15 Nov 2024

Cite this

@book{865ddb902a764ebab033dbc52105c6ed,

title = "Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909)",

author = "Alexis Llewellyn and Diarmuid Coughlan and Chinyereugo Umemneku-Chikere and Helen Fulbright and Nevitt, {Sarah Jane} and Robert Hodgson",

year = "2024",

month = nov,

day = "15",

language = "English",

publisher = "National Institute for Health and Care Excellence",

}

TY - BOOK

T1 - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909)

AU - Llewellyn, Alexis

AU - Coughlan, Diarmuid

AU - Umemneku-Chikere, Chinyereugo

AU - Fulbright, Helen

AU - Nevitt, Sarah Jane

AU - Hodgson, Robert

PY - 2024/11/15

Y1 - 2024/11/15

M3 - Commissioned report

BT - Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909)

PB - National Institute for Health and Care Excellence

ER -